Indatuximab ravtansine

Indatuximab ravtansine
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetSDC1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

It is the anti-CD138 chimerized MAb (nBT062)[1] linked to the maytansinoid DM4.[1]

It is being investigated as part of a treatment for multiple myeloma.[1]

  1. ^ a b c Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.